1. South Korea Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Celltrion Pharm, Inc.

Celltrion Pharm, Inc.

068760.KQ
Celltrion Pharm, Inc.KR flagKOSDAQ
41,000.00
KRW
+700.00
- -
1.81TMarket Cap
Celltrion Pharm, Inc.
068760.KQ
(KOSDAQ)

Recent

price

41,000.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2,180.27
2,507.45
2,454.03
2,444.27
3,205.17
2,561.04
2,829.46
3,073.66
3,314.89
3,918.64
5,369.24
8,984.6
8,701.12
8,757.55
10,770.01
12,347.05
12,552.93
Revenue per Share
189.56
185.21
185.59
121.29
281.86
-521.13
-569.77
61.42
-211.89
194.27
481.36
779.15
585.12
478.99
495.1
892
908.7
Basic EPS, GAAP
-731.09
-1,473.82
-3,942.41
-4,390.92
-851.18
-1,867.39
-834.6
-136.36
145.07
-94.87
-184.1
1,817.25
-232.87
41.86
1,140.6
1,576.93
1,183.33
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
652.85
935.99
1,140.66
1,140.62
1,569.79
-136.57
-540.06
-95.92
-635.76
635.35
1,137.23
1,894.13
2,480.47
2,958.19
3,455.4
4,420.97
4,024.01
Book Value per Share
5,169.73
5,039.09
6,023.5
5,670.82
7,573.12
5,260.35
6,376.33
5,740.01
5,285.89
5,503.06
6,034.53
6,591.66
7,110.36
7,599.31
8,062.94
9,040.59
8,431.66
Tangible Book Value per Share
18
19
19
22
21
29
37
44
44
44
44
44
44
44
44
43
44
Basic Weighted Avg Shares
40,219
46,494
46,968
52,657
66,744
74,732
104,811
135,860
146,880
173,513
233,568
398,738
386,040
388,794
477,835
536,400
555,998
Sales/Revenue/Turnover
15.14
14.47
10.81
14.23
12.51
-18.1
-14.32
6.38
2.43
8.49
10.12
11.99
9.89
9.28
7.79
10.46
10.48
Operating Margin (%)
2,380
1,647
1,160
1,050
1,187
4,442
12,069
12,234
12,712
13,023
13,470
16,378
17,419
19,725
20,093
22,249
23,192
Depreciation Expense
3,497
3,434
3,552
2,613
5,869
-15,207
-21,106
2,715
-9,389
8,602
20,940
34,579
25,960
21,265
21,966
38,752
40,248
Net Income, GAAP
35.68
2.7
- -
27.86
0.68
- -
- -
- -
- -
2.74
- -
18.68
14.8
18.86
26.19
22.05
22.69
Effective Tax Rate (%)
8.69
7.39
7.56
4.96
8.79
-20.35
-20.14
2
-6.39
4.96
8.97
8.67
6.72
5.47
4.6
7.22
7.24
Profit Margin (%)
64,962
46,935
34,237
114,273
34,864
36,860
99,455
86,816
54,926
39,717
46,027
71,226
99,920
115,485
144,023
186,976
188,857
Working Capital
30,594
32,757
64,065
165,570
84,401
114,089
89,000
48,125
34,375
38,811
57,851
39,398
21,823
5,862
15,089
16,560
15,441
LT Debt
121,805
128,268
157,246
168,412
214,426
192,314
276,706
293,624
270,035
280,031
300,561
331,969
356,787
376,666
396,922
435,963
434,821
Total Equity
2.89
4.13
- -
1.82
2.27
- -
- -
- -
- -
3.35
- -
7.72
6.28
5.51
4.93
7.42
7.65
Return on Invested Capital (%)
14.72
8.61
- -
2.29
4.34
- -
- -
- -
- -
8.87
- -
15.34
11.67
9.92
8.88
12.95
13.53
Return on Capital (%)
34.1
23.36
18.13
11.26
20.5
- -
- -
- -
- -
- -
53.97
51.79
26.75
17.62
15.43
22.44
23.76
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
153,526
144,755
145,140
LT Borrowings
- -
- -
- -
LT Finance Leases
17,223
16,560
15,441
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
44
44
Market Capitalization
2,386,847
2,587,610
2,427,218

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
464,496
470,598
481,571
Cash, Cash Equivalents & STI
122,762
116,929
133,914
Accounts Receivable, Net
204,845
220,287
209,060
Inventories
129,886
122,936
125,999
Total Current Liabilities
287,632
283,622
292,714
Payables & Accruals
- -
- -
- -
ST Debt
153,526
144,755
145,140
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.17%
7.74%
9.84%
Free Cash Flow
91.54%
264.11%
35.38%
Net Income, GAAP
-46.63%
20.37%
76.42%
Sales/Revenue/Turnover
23.41%
20.68%
12.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
96,969
117,155
128,130
135,582
477,835
2025
112,524
131,298
138,175
154,404
536,400
2026
132,122
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
41.08
120.45
178.34
- -
495.1
2025
161.76
250.36
258.71
- -
892
2026
199.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Medico Remedies Limited (MEDICO.BO)
The Green Organic Dutchman Holdings Ltd. (GRODF)
Aarey Drugs & Pharmaceuticals (AAREYDRUGS.BO)
Entourage Health Corp. (ETRGF)
BioHarvest Sciences Inc. (CNVCF)
Incannex Healthcare Limited (IHL.AX)
Business
Celltrion Pharm, Inc. (068760.KQ) develops, manufactures, and sells biosimilars, chemical pharmaceuticals, and over-the-counter drugs primarily in South Korea. The company offers a diverse portfolio including hepatotonic agents such as GODEX Cap.; anti-inflammatory, antihistamine, respiratory, circulatory system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic preparations; immunology products like Remsima (infliximab biosimilar), Truxima (rituximab biosimilar), and Herzuma (trastuzumab biosimilar); oncology drugs; and other therapeutic categories, with contract manufacturing organization (CMO) services utilizing global-standard facilities. It serves university hospitals, general pharmacies, and international markets, focusing on high-quality biopharmaceuticals and chemical products. Founded in 1976 and headquartered in Cheongju-si, South Korea, Celltrion Pharm operates within the drug manufacturers-specialty and generic industry segment, emphasizing R&D and production for domestic and export markets. In recent developments, Celltrion Pharm supports group-wide expansions including the November 2024 acquisition of iQone Healthcare Switzerland by its affiliate Celltrion to bolster European biosimilar distribution; the U.S. FDA approval in December 2025 of a 300mg strength for OMLYCLO (omalizumab-igec), an interchangeable biosimilar; and the September 2025 purchase of an Eli Lilly drug substance plant in the U.S. for $330 million to enhance manufacturing capacity and revenue streams. These moves align with strategic shifts toward global market penetration, pipeline diversification with launches like Eydenzelt and SteQeyma, and a target of 22 biosimilars by 2030. The company maintains affiliations within the Celltrion group, leveraging shared expertise in biopharmaceutical innovation.